Using Clinical Decision Support Tools To Facilitate Decision-Making In Precision Medicine

Using Clinical Decision Support Tools To Facilitate Decision-Making In Precision Medicine

Publication date: Nov 06, 2019

Getty To fulfill its promise precision medicine requires accurate decision support tools, especially to streamline biomarker testing so that the appropriate targeted therapies are prescribed.

Even in oncology, where precision medicine has advanced the farthest compared to other therapeutic categories, clinical decision tools are needed to sort through and analyze reams of clinical and molecular data for the purpose of optimizing treatment algorithms.

Elsevier’s Via Oncology, for example, operates a clinical decision support tool called Via Pathways, designed to inform the appropriate use of biomarker tests and corresponding targeted therapies.

According to recently released precision medicine cancer treatment clinical trial Molecular Analysis for Therapy Choice (MATCH) only 15% of common tumors tested have actionable mutations.

Other companies that focus on clinical decision support tools, such as Tempus, are attempting to harness the power of AI.

Here, clinical decision tools, AI, and Big Data are changing the landscape.

Concepts Keywords
AI Diagnostic tests
Artificial Intelligence Artificial intelligence
Assimilation Drug design
Biomarker Treatment algorithms
Biomarkers Prior authorization protocols
Biopharmaceutical Targeted therapy
Breast Clinical trial
Clinical Trial Chemical pathology
Drug Design Medical signs
Elsevier Biotechnology
Healthcare Biomarkers
Image Recognition Health
Lung Clinical medicine
Mutation Medicine
Oncology Drug therapies
Optum Molecular Therapy
Pharmaceutical Common tumors
Survey Sub population product
Targeted Therapies Clinical tools
Targeted Therapy Label extensions products
Prior authorization protocols
Treatment algorithms


Type Source Name
disease MESH development
disease DOID cancer
disease MESH cancer
drug DRUGBANK Pembrolizumab
drug DRUGBANK Nivolumab
gene UNIPROT CD274
pathway BSID Non-small cell lung cancer
disease DOID non-small cell lung cancer
disease MESH non-small cell lung cancer


Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *